ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Universitetsbiblioteket
  • Artikler, rapporter og annet (UB)
  • Vis innførsel
  •   Hjem
  • Universitetsbiblioteket
  • Artikler, rapporter og annet (UB)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer

Permanent lenke
https://hdl.handle.net/10037/25666
DOI
https://doi.org/10.1038/bjc.2012.293
Thumbnail
Åpne
article.pdf (990.4Kb)
Publisert versjon (PDF)
Dato
2012-07-10
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Boye, Kjetil; Nesland, Jahn M; Sandstad, Berit; Haugen, Mads Haugland; Mælandsmo, Gunhild; Flatmark, Kjersti
Sammendrag
BACKGROUND: Proteolytic enzymes and their regulators have important biological roles in colorectal cancer by stimulating invasion and metastasis, which makes these factors attractive as potential prognostic biomarkers. METHODS: The expression of extracellular matrix metalloproteinase inducer (EMMPRIN) was characterised using immunohistochemistry in primary tumours from a cohort of 277 prospectively recruited colorectal cancer patients, and associations with expression of S100A4, clinicopathological parameters and patient outcome were investigated. RESULTS: One hundred and ninety-eight samples (72%) displayed positive membrane staining of the tumour cells, whereas 10 cases (4%) were borderline positive. EMMPRIN expression was associated with shorter metastasis-free, disease-specific and overall survival in both univariate and multivariate analyses. The prognostic impact was largely confined to TNM stage III, and EMMPRIN-negative stage III patients had an excellent prognosis. Furthermore, EMMPRIN was significantly associated with expression of S100A4, and the combined expression of these biomarkers conferred an even poorer prognosis. However, there was no evidence of direct regulation between the two proteins in the colorectal cancer cell lines HCT116 and SW620 in siRNA knockdown experiments. CONCLUSION: EMMPRIN is a promising prognostic biomarker in colorectal cancer, and our findings suggest that it could be used in the selection of stage III patients for adjuvant therapy.
Forlag
Nature
Sitering
Boye KB, Nesland JM, Sandstad B, Haugen MH, Mælandsmo GM, Flatmark K. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. British Journal of Cancer. 2012;107(4):667-674
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (UB) [3249]
Copyright 2012 Cancer Research UK

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring